Alzheimer’s disease drug developed at Roskamp Institute approved for key clinical trial funding in Europe

Nilvadipine, an Alzheimer’s drug developed at the Roskamp Institute in Sarasota announced earlier this year was selected for funding or a large-scale European clinical trial. An international research consortium led by Trinity College Dublin (Ireland) announced more than 500 patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of […]

Continue reading


Roskamp institute studies may lead to better diagnosis

Researchers at the Roskamp Institute have new studies that could lead to better diagnosis and eventual treatment for U.S. military personnel as well as other patients with TBI, commonly known as traumatic brain injuries. Fiona Crawford, Ph.D., associate director of the Institute, a leading research facility for Alzheimer’s disease and other neurological disorders says, “We […]

Continue reading


Dr. Mullan’s Alzheimer Research Involved Studying Brain Proteins

The Roskamp Institute has surfaced as a leading and reputable non-for-profit biomedical research organization. It has successfully experimented to find cures for several neurodegenerative disorders and conditions like Alzheimer’s disease. Through the clinical trials division and outpatient clinic, at the institute, thousands of Alzheimer’s patients get superior services and therapeutic treatments. Dr. Michael Mullan is […]

Continue reading


Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers.

The Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers. Drs. Corbin Bachmeier, Daniel Paris, and Michael Mullan at the Roskamp Institute have been working on ways to improve the removal of the Alzheimer amyloid peptide from the brain. Using […]

Continue reading


Mullan Alzheimer Research Institute Roskamp Institute aids high school students in genetic research

Dr. Mullan Alzheimer Research Institute helps high school student to be involved in research……… Roskamp Institute aids high school students in genetic research Roskamp aids high school students in genetic research By JENNIFER RICH – jrich@bradenton.com They look like scientists in their white coats, working in the Roskamp Institute’s lab using microscopes and high-tech research […]

Continue reading


The Roskamp Institute investigates the role of anatabine in lowering Alzheimer’s Abeta levels.

The Roskamp Institute has had a long-term interest in finding new treatments for Alzheimer’s disease. Central to the goal of the institute is finding new ways to lower the accumulation of Alzheimers Abeta peptide in the brain. Drs. Michael Mullan and Daniel Paris and colleague investigated the role of an extract of tobacco, known as […]

Continue reading


Dr. Mullan Alzheimer Presentation at Pines of Sarasota

Alzheimer’s disease: Amyloid Plaque (Excerpt from “On The Forefront”)  Video shows Dr. Michael Mullan (Dr. Mullan Alzheimer Researcher at the Roskamp Institute) presenting information to audience about Alzheimer’s Disease.Beta Amyloid Presentation By Dr. Michael Mullan (Mullan Alzheimer Researcher)

Continue reading


Roskamp Institute Celebrated Veterans Day with a seminar by Alzheimer Researcher Dr. Michael Mullan

Dr. Fiona Crawford presentedVideo of Alzheimer Research Institute Headed By Dr. Mullan Presentation on Traumatic Brain Injury a synopsis of her recent study of traumatic brain injury (TBI). Her recently published findings show how TBI can affect the brain’s inflammatory mechanisms, changes in protein levels and cellular pathways, long after the original trauma. Dr. Crawford’s […]

Continue reading


Alzheimer Researcher Dr. Michael Mullans Note on Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide.

A study entitled “Potent anti-angiogenic motifs within the Alzheimer’s β-amyloid peptide” was published in the January 2008 issue of the journal Amyloid. Building on previous work by Dr. Michael Mullan showing that the Alzheimer’s Aβ peptide is able to prevent blood vessel growth and inhibit tumor growth, Dr. Michael Mullan and other Roskamp Institute scientists […]

Continue reading


Effect of NSAIDS on cognitive ability of Alzheimer’s Patient — Comment by Alzheimer Researcher Mullan

Medications that reduce inflammation known as non-steroidal anti-inflammatory drugs (NSAIDS) do not improve thinking abilities in normal seniors.  These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology. The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that […]

Continue reading


Dr. Mullan’s Alzheimer Research Notes on NSAIDS and their effect on Alzheimers disease

Non-steroidal anti-inflammatory (NSAIDS) drugs such as Naproxen and Celecoxib do not improve cognition in at-risk older adults. These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology. The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that took […]

Continue reading